Literature DB >> 31001618

Changing Characteristics of Staphylococcus aureus Bacteremia: Results From a 21-Year, Prospective, Longitudinal Study.

Maria Souli1,2,3, Felicia Ruffin1, Seong-Ho Choi1,4, Lawrence P Park1,5, Shengli Gao1,6, Nicholas Christopoulos Lent1, Batu K Sharma-Kuinkel1, Joshua T Thaden1, Stacey A Maskarinec1, Lisa Wanda1,7, Jonathan Hill-Rorie1,8, Bobby Warren1, Brenda Hansen1,9, Vance G Fowler1,2.   

Abstract

BACKGROUND: We conducted a longitudinal study to evaluate changes in the clinical presentation and epidemiology of Staphylococcus aureus bacteremia (SAB) in an academic, US medical center.
METHODS: Consecutive patients with monomicrobial SAB were enrolled from January 1995 to December 2015. Each person's initial bloodstream S. aureus isolate was genotyped using spa typing. Clonal complexes (CCs) were assigned using Ridom StaphType software. Changes over time in both the patient and bacterial characteristics were estimated with linear regression. Associations between genotypes or clinical characteristics and complications were estimated using multivariable regression models.
RESULTS: Among the 2348 eligible participants, 54.2% had an implantable, foreign body of some type. This proportion increased significantly during the 21-year study period, by 0.96% annually (P = .002), as did comorbid conditions and acquisition outside of the hospital. Rates of any metastatic complication also significantly increased, by 0.94% annually (P = .019). Among the corresponding bloodstream S. aureus isolates, spa-CC012 (multi-locus sequence type [MLST] CC30), -CC004 (MLST CC45), -CC189 (MLST CC1), and -CC084 (MLST CC15) all significantly declined during the study period, while spa-CC008 (MLST CC8) significantly increased. Patients with SAB due to spa-CC008 were significantly more likely to develop metastatic complications in general, and abscesses, septic emboli, and persistent bacteremia in particular. After adjusting for demographic, racial, and clinical variables, the USA300 variant of spa-CC008 was independently associated with metastatic complications (odds ratio 1.42; 95% confidence interval 1.02-1.99).
CONCLUSIONS: Systematic approaches for monitoring complications of SAB and genotyping the corresponding bloodstream isolates will help identify the emergence of hypervirulent clones and likely improve clinical management of this syndrome.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 spa typing; zzm321990 spa-CC008; MRSA; USA300; clonal complex

Year:  2019        PMID: 31001618      PMCID: PMC6853684          DOI: 10.1093/cid/ciz112

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  38 in total

1.  Potential associations between hematogenous complications and bacterial genotype in Staphylococcus aureus infection.

Authors:  Vance G Fowler; Charlotte L Nelson; Lauren M McIntyre; Barry N Kreiswirth; Alastair Monk; Gordon L Archer; Jerome Federspiel; Steven Naidich; Brian Remortel; Thomas Rude; Pamela Brown; L Barth Reller; G Ralph Corey; Steven R Gill
Journal:  J Infect Dis       Date:  2007-07-20       Impact factor: 5.226

2.  Continued expansion of USA300-like methicillin-resistant Staphylococcus aureus (MRSA) among hospitalized patients in the United States.

Authors:  Isabella A Tickler; Richard V Goering; Jose R Mediavilla; Barry N Kreiswirth; Fred C Tenover
Journal:  Diagn Microbiol Infect Dis       Date:  2017-05-06       Impact factor: 2.803

3.  Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections.

Authors:  N Deborah Friedman; Keith S Kaye; Jason E Stout; Sarah A McGarry; Sharon L Trivette; Jane P Briggs; Wanda Lamm; Connie Clark; Jennifer MacFarquhar; Aaron L Walton; L Barth Reller; Daniel J Sexton
Journal:  Ann Intern Med       Date:  2002-11-19       Impact factor: 25.391

4.  Methicillin-susceptible Staphylococcus aureus endocarditis isolates are associated with clonal complex 30 genotype and a distinct repertoire of enterotoxins and adhesins.

Authors:  Juhsien J C Nienaber; Batu K Sharma Kuinkel; Michael Clarke-Pearson; Supaporn Lamlertthon; Lawrence Park; Thomas H Rude; Steve Barriere; Christopher W Woods; Vivian H Chu; Mercedes Marín; Suzana Bukovski; Patricia Garcia; G Ralph Corey; Tony Korman; Thanh Doco-Lecompte; David R Murdoch; L Barth Reller; Vance G Fowler
Journal:  J Infect Dis       Date:  2011-09-01       Impact factor: 5.226

Review 5.  Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology.

Authors:  Fred C Tenover; Richard V Goering
Journal:  J Antimicrob Chemother       Date:  2009-07-16       Impact factor: 5.790

6.  USA300 methicillin-resistant Staphylococcus aureus emerging as a cause of bloodstream infections at military medical centers.

Authors:  Jeffrey Sherwood; Matthew Park; Paul Robben; Timothy Whitman; Michael W Ellis
Journal:  Infect Control Hosp Epidemiol       Date:  2013-02-15       Impact factor: 3.254

7.  α-Hemolysin, not Panton-Valentine leukocidin, impacts rabbit mortality from severe sepsis with methicillin-resistant Staphylococcus aureus osteomyelitis.

Authors:  Anne-Claude Crémieux; Azzam Saleh-Mghir; Claire Danel; Florence Couzon; Oana Dumitrescu; Thomas Lilin; Christian Perronne; Jérôme Etienne; Gerard Lina; François Vandenesch
Journal:  J Infect Dis       Date:  2013-12-26       Impact factor: 5.226

Review 8.  The changing epidemiology of Staphylococcus aureus?

Authors:  H F Chambers
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

9.  Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis.

Authors:  Binh An Diep; Amy M Palazzolo-Ballance; Pierre Tattevin; Li Basuino; Kevin R Braughton; Adeline R Whitney; Liang Chen; Barry N Kreiswirth; Michael Otto; Frank R DeLeo; Henry F Chambers
Journal:  PLoS One       Date:  2008-09-12       Impact factor: 3.240

10.  spa Typing and Multilocus Sequence Typing Show Comparable Performance in a Macroepidemiologic Study of Staphylococcus aureus in the United States.

Authors:  F Patrick O'Hara; Jose A Suaya; G Thomas Ray; Roger Baxter; Megan L Brown; Robertino M Mera; Nicole M Close; Elizabeth Thomas; Heather Amrine-Madsen
Journal:  Microb Drug Resist       Date:  2015-12-15       Impact factor: 3.431

View more
  29 in total

1.  Long-term methicillin-resistant Staphylococcus aureus bacteremia persisting for more than 2 weeks: risk factors and outcomes.

Authors:  Yu-Mi Lee; Yong Pil Chong; Minjeong Kim; Yewon Eom; Eun Sil Kim; Miyoung Kim; Ki-Ho Park; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jun Hee Woo; Yang Soo Kim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-23       Impact factor: 3.267

2.  Staphylococcus aureus Bacteremia: Contemporary Management.

Authors:  Leny Abraham; David M Bamberger
Journal:  Mo Med       Date:  2020 Jul-Aug

3.  Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis.

Authors:  Vance G Fowler; Anita F Das; Joy Lipka-Diamond; Raymond Schuch; Roger Pomerantz; Luis Jáuregui-Peredo; Adam Bressler; David Evans; Gregory J Moran; Mark E Rupp; Robert Wise; G Ralph Corey; Marcus Zervos; Pamela S Douglas; Cara Cassino
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

4.  Microbial Cell-Free DNA Identifies Etiology of Bloodstream Infections, Persists Longer Than Conventional Blood Cultures, and Its Duration of Detection Is Associated With Metastatic Infection in Patients With Staphylococcus aureus and Gram-Negative Bacteremia.

Authors:  Emily M Eichenberger; Christiaan R de Vries; Felicia Ruffin; Batu Sharma-Kuinkel; Lawrence Park; David Hong; Erick R Scott; Lily Blair; Nicholas Degner; Desiree H Hollemon; Timothy A Blauwkamp; Carine Ho; Hon Seng; Pratik Shah; Lisa Wanda; Vance G Fowler; Asim A Ahmed
Journal:  Clin Infect Dis       Date:  2022-06-10       Impact factor: 20.999

5.  Clinical impact of and microbiological risk factors for qacA/B positivity in ICU-acquired ST5-methicillin-resistant SCCmec type II Staphylococcus aureus bacteremia.

Authors:  Haein Kim; Sunghee Park; Hyeonji Seo; Hyemin Chung; Eun Sil Kim; Heungsup Sung; Mi-Na Kim; Seongman Bae; Jiwon Jung; Min Jae Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Yong Pil Chong
Journal:  Sci Rep       Date:  2022-07-06       Impact factor: 4.996

6.  Early Oral Antibiotic Switch for Staphylococcus aureus Bacteremia: Many Are Called, but Few Are Chosen.

Authors:  Thomas L Holland
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 7.  Current Paradigms of Combination Therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination, and For Which Patients?

Authors:  Warren Rose; Michael Fantl; Matthew Geriak; Victor Nizet; George Sakoulas
Journal:  Clin Infect Dis       Date:  2021-12-16       Impact factor: 9.079

8.  Bacterial genotype and clinical outcomes in solid organ transplant recipients with Staphylococcus aureus bacteremia.

Authors:  Emily M Eichenberger; Felicia Ruffin; Batu Sharma-Kuinkel; Michael Dagher; Lawrence Park; Celia Kohler; Matthew R Sinclair; Stacey A Maskarinec; Vance G Fowler
Journal:  Transpl Infect Dis       Date:  2021-12-16       Impact factor: 2.228

9.  Staphylococcus aureus Bacteremia Among Patients Receiving Maintenance Hemodialysis: Trends in Clinical Characteristics and Outcomes.

Authors:  Matthew R Sinclair; Maria Souli; Felicia Ruffin; Lawrence P Park; Michael Dagher; Emily M Eichenberger; Stacey A Maskarinec; Joshua T Thaden; Michael Mohnasky; Christina M Wyatt; Vance G Fowler
Journal:  Am J Kidney Dis       Date:  2021-07-23       Impact factor: 8.860

10.  Duration of antibiotic therapy for Staphylococcus aureus bacteraemia: the long and the short of it.

Authors:  E M Eichenberger; V G Fowler; T L Holland
Journal:  Clin Microbiol Infect       Date:  2020-01-20       Impact factor: 13.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.